Contracts › 75F40122C00202
75F40122C00202: Pmqwp 345/Cder-2022-113555 - Improve Scientific Approaches to Evaluate Generic Drugs.
Awarded to University of Sydney by Food and Drug Administration (FDA).
$1.2Mobligated
$1.2Mpotential value
29 September 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75F40122C00202 |
|---|---|
| Awardee | University of Sydney |
| Awarding agency | Food and Drug Administration (FDA) |
| Awarding office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | MD |
| Offers received | 165 |
| Period of performance | 27 September 2022 to 29 September 2026 |
| Potential end | 29 September 2026 |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record